Circulating Vitamin D and Overall Survival in Breast Cancer Patients: A Dose-Response Meta-Analysis of Cohort Studies
Open Access
- 7 June 2017
- journal article
- research article
- Published by SAGE Publications in Integrative Cancer Therapies
- Vol. 17 (2), 217-225
- https://doi.org/10.1177/1534735417712007
Abstract
Studies have shown that vitamin D could have a role in breast cancer survival; however, the evidence of the relationship between patients’ vitamin D levels and their survival has been inconsistent. This meta-analysis explores possible dose-response relationships between vitamin D levels and overall survival by allowing for differences in vitamin D levels among populations of the various studies. Studies relating vitamin D (25-OH-D [25-hydroxyvitamin D]) levels in breast cancer patients with their survival were identified by searching PubMed and Embase. A pooled HR (hazard ratio) comparing the highest with the lowest category of circulating 25-OH-D levels were synthesized using the Mantel-Haenszel method under a fixed-effects model. A two-stage fixed-effects dose-response model including both linear (a log-linear dose-response regression) and nonlinear (a restricted cubic spline regression) models were used to further explore possible dose-response relationships. Six studies with a total number of 5984 patients were identified. A pooled HR comparing the highest with the lowest category of circulating 25-OH-D levels under a fixed-effects model was 0.67 (95% confidence interval = 0.56-0.79, P < .001). Utilizing a dose-response meta-analysis, the pooled HR for overall survival in breast cancer patients was 0.994 (per 1 nmol/L), Pfor linear trend < .001. At or above a 23.3 nmol/L threshold, for a 10 nmol/L, 20 nmol/L, or 25 nmol/L increment in circulating 25-OH-D levels, the risk of breast cancer overall mortality decreased by 6%, 12%, and 14%, respectively. There was no significant nonlinearity in the relationship between overall survival and circulating 25-OH-D levels. Our findings suggest that there is a highly significant linear dose-response relationship between circulating 25-OH-D levels and overall survival in patients with breast cancer. However, better designed prospective cohort studies and clinical trials are needed to further confirm these findings.Keywords
This publication has 58 references indexed in Scilit:
- Egg consumption and risk of coronary heart disease and stroke: dose-response meta-analysis of prospective cohort studiesBMJ, 2013
- Serum levels of 25-hydroxyvitamin D and survival in Norwegian patients with cancer of breast, colon, lung, and lymphoma: a population-based studyCancer Causes & Control, 2011
- Serum 25-hydroxyvitamin D and postmenopausal breast cancer survival: a prospective patient cohort studyBreast Cancer Research, 2011
- Inhibitory Effects of Calcitriol on the Growth of MCF-7 Breast Cancer Xenografts in Nude Mice: Selective Modulation of Aromatase Expression in vivoHormones and Cancer, 2011
- Dietary Intake, Supplement Use, and Survival Among Women Diagnosed With Early-Stage Breast CancerNutrition and Cancer, 2011
- Vitamin Supplement Use During Breast Cancer Treatment and Survival: A Prospective Cohort StudyCancer Epidemiology, Biomarkers & Prevention, 2011
- Tissue-Selective Regulation of Aromatase Expression by Calcitriol: Implications for Breast Cancer TherapyEndocrinology, 2010
- Prognostic Effects of 25-Hydroxyvitamin D Levels in Early Breast CancerJournal of Clinical Oncology, 2009
- Facilitating meta‐analyses by deriving relative effect and precision estimates for alternative comparisons from a set of estimates presented by exposure level or disease categoryStatistics in Medicine, 2007
- Quantifying heterogeneity in a meta-analysisStatistics in Medicine, 2002